Arena posted a Q3 net loss of $0.54 per share versus a loss of $0.43 for the year-ago quarter. Quarterly revenue did increase a little because of money from collaboration agreements with Merck
Among potential candidates, lorcaserin and APD125 are the furthest along, although Arena does have an anti-thrombotic candidate and a type-2 diabetes drug in phase 1 trials. Given that it will be some time before the company can bring one of these products to market, it looks as though it will have to continue to endure some more quarters in the red.
Arena isn't in a cash crunch now, but it will be important to see more progress from the company's pipeline if the market is to reverse the decrease in the stock price over the last year and a half.
For related Foolishness: